公开(公告)号：US20180037655A1

公开(公告)日：2018-02-08

申请号：US15790680

申请日：2017-10-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20180030138A1

公开(公告)日：2018-02-01

申请号：US15787988

申请日：2017-10-19

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57423 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).

公开(公告)号：US20160009805A1

公开(公告)日：2016-01-14

申请号：US14726329

申请日：2015-05-29

Applicant: GENENTECH, INC. ,  SPRING BIOSCIENCE CORPORATION ,  VENTANA MEDICAL SYSTEMS, INC.

Inventor： Marcin KOWANETZ ,  Hartmut KOEPPEN ,  Zachary BOYD ,  Zhiming LIAO ,  Yifei ZHU ,  Bharathi VENNAPUSA ,  Patrick C. ROCHE

IPC: C07K16/28 ,  G01N33/574 ,  A61K39/395 ,  C07K14/705 ,  A61K45/06

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K45/06 ,  A61N2005/1021 ,  C07K14/70532 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30 ,  G01N33/53 ,  G01N33/57484 ,  G01N2500/10 ,  G01N2800/52

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract translation: 本发明提供程序性死亡 - 配体1（PD-L1）抗体及其使用方法。

公开(公告)号：US20240190967A1

公开(公告)日：2024-06-13

申请号：US18237114

申请日：2023-08-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  A61K39/00 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: C07K16/2827 ,  C12Q1/6886 ,  G01N33/57407 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20220363764A1

公开(公告)日：2022-11-17

申请号：US17686628

申请日：2022-03-04

Applicant: Genentech, Inc.

Inventor： Daniel Shin-Yu CHEN ,  Priti HEGDE ,  Hartmut KOEPPEN ,  Marcin KOWANETZ

IPC: C07K16/28 ,  G01N33/574 ,  C12Q1/6886 ,  G01N33/68 ,  G06Q30/02

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US20180313845A1

公开(公告)日：2018-11-01

申请号：US16035238

申请日：2018-07-13

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ ,  Daniel Shin-Yu CHEN ,  Hartmut KOEPPEN

IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  G06Q30/02 ,  A61K39/395 ,  A61K45/06

CPC classification number: G01N33/57492 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2827 ,  C07K16/30 ,  C07K2317/73 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/70532 ,  G06Q30/0241 ,  G06Q30/0251

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US20170052188A1

公开(公告)日：2017-02-23

申请号：US15197572

申请日：2016-06-29

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ ,  Daniel Shin-Yu CHEN ,  Hartmut KOEPPEN

IPC: G01N33/574 ,  G06Q30/02 ,  A61K39/395 ,  A61K45/06 ,  C12Q1/68 ,  C07K16/28

CPC classification number: G01N33/57492 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2827 ,  C07K16/30 ,  C07K2317/73 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/70532 ,  G06Q30/0241 ,  G06Q30/0251

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

Abstract translation: 本文提供了用于治疗诸如癌症的病理状况的生物标志物和使用PD-1 / PD-L1途径拮抗剂的方法。 特别地，提供了用于癌症中的患者选择和预后的生物标志物，以及治疗性治疗方法，制造物品及其制备方法，诊断试剂盒，检测方法和与其相关的广告方法。

公开(公告)号：US20250164494A1

公开(公告)日：2025-05-22

申请号：US19028633

申请日：2025-01-17

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ ,  Daniel Shin-Yu CHEN ,  Hartmut KOEPPEN

IPC: G01N33/574 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  G06Q30/0241 ,  G06Q30/0251

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US20220146517A1

公开(公告)日：2022-05-12

申请号：US17403349

申请日：2021-08-16

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ ,  Daniel Shin-Yu CHEN ,  Hartmut KOEPPEN

IPC: G01N33/574 ,  C12Q1/6886 ,  G06Q30/02 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US20220073623A1

公开(公告)日：2022-03-10

申请号：US17535898

申请日：2021-11-26

Applicant: Genentech, Inc.

Inventor： Marcin KOWANETZ

IPC: C07K16/28 ,  G01N33/574 ,  C12Q1/6886

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).